Bech P
Department of Psychiatry, Frederiksborg General Hospital, Hillerød, Denmark.
Acta Psychiatr Scand Suppl. 1988;345:45-55. doi: 10.1111/j.1600-0447.1988.tb08567.x.
Rating scales for mood disorders have been reviewed with special reference to their consistency, applicability, and validity. Diagnostic scales with a biometric reference to antidepressants have been developed on the basis of the Newcastle Scales. This Diagnostic Melancholia Scale (DMS) includes two dimensions, one measuring endogenous depression, and one measuring reactive depression. These dimensions were found not to be mutually exclusive as 30% of the depressed patients scored high on both dimensions. Scales measuring outcomes of treatment were subdivided into (a) scales measuring disability of clinical depression (melancholia), anxiety, and mania, (b) scales measuring distress as a construct of side-effects during treatment, and (c) scales measuring discomfort or quality of life. Disability, distress and discomfort should be separately validated as they reflect different aspects of outcome of treatment. Self-rating scales have their main applicability in the measurement of discomfort.
情绪障碍评定量表已被特别参照其一致性、适用性和效度进行了综述。基于纽卡斯尔量表开发了具有抗抑郁药生物统计学参考的诊断量表。这种诊断性忧郁症量表(DMS)包括两个维度,一个测量内源性抑郁,另一个测量反应性抑郁。发现这些维度并非相互排斥,因为30%的抑郁症患者在两个维度上得分都很高。测量治疗结果的量表可细分为:(a)测量临床抑郁症(忧郁症)、焦虑症和躁狂症残疾程度的量表;(b)测量治疗期间作为副作用结构的痛苦程度的量表;(c)测量不适或生活质量的量表。残疾、痛苦和不适应分别进行验证,因为它们反映了治疗结果的不同方面。自评量表在测量不适方面具有主要适用性。